|
Level
|
Code
|
Display
|
Definition
|
| 1 |
(_ActSubstanceAdminSubstitutionCode)
Abstract
|
|
Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
|
| 2 |
E
|
equivalent |
Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
|
| 3 |
EC
|
equivalent composition |
Description:
Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration
Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
Pharmaceutical equivalent: Lisonpril for Zestril
|
| 4 |
BC
|
brand composition |
Description:
Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil
Coumadin for Jantoven
|
| 4 |
G
|
generic composition |
Description: Substitution occurred or is permitted between equivalent Generics but not Brands
Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
|
| 3 |
TE
|
therapeutic alternative |
Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
Examples:
ranitidine for Tagamet
|
| 4 |
TB
|
therapeutic brand |
Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
>
Examples:
Zantac for Tagamet
|
| 4 |
TG
|
therapeutic generic |
Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
>
Examples:
Ranitidine for cimetidine
|
| 2 |
F
|
formulary |
Description: This substitution was performed or is permitted based on formulary guidelines.
|
| 2 |
N
|
none |
No substitution occurred or is permitted.
|